Jane Street
TNXP icon

Jane Street’s Tonix Pharmaceuticals TNXP Stock Holding History

Jane Street’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,626
Closed -$471K – 12991
2025
Q4 		$478K Buy
+30,626
New +$565K ﹤0.01% 7792
2025
Q1 		– Sell
-16,627
Closed -$548K – 10612
2024
Q4 		$548K Buy
16,627
+16,351
+5,924% +$340K ﹤0.01% 6594
2024
Q3 		$4.09K Buy
276
+166
+151% +$6.68K ﹤0.01% 9413
2024
Q2 		$7.64K Buy
110
+106
+2,650% +$48.1K ﹤0.01% 9133
2024
Q1 		$2.55K Buy
+4
New +$4.31K ﹤0.01% 9053
2023
Q1 		– Sell
-1
Closed -$5.94K – 9933
2022
Q4 		$5.94K Hold
1
– – ﹤0.01% 8834
2022
Q3 		$13K Hold
1
– – ﹤0.01% 9297
2022
Q2 		$17K Buy
+1
New +$73.8K ﹤0.01% 9205
2022
Q1 		– Hold
0
– – – 9831
2021
Q4 		– Hold
0
– – – 9184
2021
Q3 		– Hold
0
– – – 9559
2021
Q2 		– Hold
0
– – – 9666
2020
Q3 		– Hold
0
– -$38K – 7913
2020
Q2 		– Hold
0
– – – 6901
2019
Q2 		– Hold
0
– -$29K – 5739
2019
Q1 		– Hold
0
– – – 4879

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jane Street's TNXP Position: Q1 2026 in Review

Jane Street sold out of Tonix Pharmaceuticals (TNXP) in Q1 2026, closing a stake of 30,626 shares — an estimated $471K sold.

Jane Street first reported a position in TNXP in Q2 2022 and held it in 8 quarters. The position peaked at $548K in Q4 2024. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Jane Street reported no remaining Tonix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 30,626 Tonix Pharmaceuticals shares in Q1 2026, an estimated $471K.
  • Jane Street first reported a position in Tonix Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Jane Street's Tonix Pharmaceuticals position peaked at $548K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.